Key result
Dual L-type and T-type Ca2+ channel blockers, such as efonidipine, offer potential therapeutic benefits for cardiovascular disorders by minimizing reflex tachycardia and providing renal protection.
T-type Ca2+ channel blockers, particularly dual L/T-type blockers like efonidipine, offer therapeutic advantages in cardiovascular disease by lowering blood pressure without inducing reflex tachycardia.
Hypothesis-generating for dual L/T Ca2+ blockade in hypertension; RCTs needed before practice change.
T-type Ca(2+) channels are present in cardiovascular, neuronal, and endocrine systems; and they are now receiving attention as novel therapeutic targets. Many drugs and compounds non-specificaly block T-type Ca(2+) channels. Certain dihydropyridine compounds, such as efonidipine, have blocking activity on both L-type and T-type Ca(2+) channels which possibly underlies their excellent clinical profiles such as minimum reflex tachycardia and renal protection. Selective inhibitors of T-type Ca(2+) channels, such as non-hydrolyzable mibefradil and R(-)-efonidipine, are powerful pharmacological tools for further studies and may lead to the development of novel therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2005) conducted a review in Cardiovascular disorders. T-type Ca2+ channel blockers (e.g., efonidipine, mibefradil) was evaluated. Dual L-type and T-type Ca2+ channel blockers, such as efonidipine, offer potential therapeutic benefits for cardiovascular disorders by minimizing reflex tachycardia and providing renal protection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: